Evidence map›Paper›PMID 40758833›Full record

ArticleG3 (Bethesda, Md.)2025

Improved vectors for retron-mediated CRISPR-Cas9 genome editing in Saccharomyces cerevisiae.

Tara N Stuecker, Stephanie E Hood, Julio Molina Pineda, Sonali Lenaduwe, Joshua Winter, Meru J Sadhu, Jeffrey A Lewis

Abstract read
In one paragraph

Article in G3 (Bethesda, Md.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Tara N StueckerDepartment of Biological Sciences, University of Arkansas, Fayetteville, AR 72701, United States.
Stephanie E HoodDepartment of Biological Sciences, University of Arkansas, Fayetteville, AR 72701, United States.
Julio Molina PinedaDepartment of Biological Sciences, University of Arkansas, Fayetteville, AR 72701, United States.ORCID 0009-0009-4759-1585
Sonali LenaduweDepartment of Biological Sciences, University of Arkansas, Fayetteville, AR 72701, United States.
Joshua WinterDepartment of Biological Sciences, University of Arkansas, Fayetteville, AR 72701, United States.
Meru J SadhuComputational and Statistical Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, United States.
Jeffrey A LewisDepartment of Biological Sciences, University of Arkansas, Fayetteville, AR 72701, United States.ORCID 0000-0003-2952-9701

Funding

Understanding Hesitant AdoptersP20GM103429 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Lawrence E Cornett · 2012 to 2026
$60.9M
Arkansas IDeA Network of Biomedical Research ExcellenceNational Science Foundation MCB-1941824NHGRI NIH HHSNIGMS NIH HHS P20 GM103429NIH HHS 1ZIAHG200401Summer Research Fellowship
6 · The paper itself

Abstract

In vivo site-directed mutagenesis is a powerful genetic tool for testing the effects of specific alleles in their normal genomic context. While the budding yeast Saccharomyces cerevisiae possesses classical tools for site-directed mutagenesis, more efficient recent CRISPR-based approaches use Cas "cutting" combined with homologous recombination of a "repair" template that introduces the desired edit. However, current approaches are limited for fully prototrophic yeast strains and rely on relatively low-efficiency cloning of short gRNAs. We were thus motivated to simplify the process by combining the gRNA and its cognate repair template in cis on a single oligonucleotide. Moreover, we wished to take advantage of a new approach that uses an Escherichia coli retron (EcRT) to amplify repair templates as multi-copy single-stranded (ms)DNA in vivo, which are more efficient templates for homologous recombination. To this end, we have created a set of plasmids that express Cas9-EcRT, allowing for co-transformation with the gRNA-repair template plasmid in a single step. Our suite of plasmids contains different antibiotic (Nat, Hyg, Kan) or auxotrophic (HIS3, URA3) selectable markers, allowing for editing of fully prototrophic wild yeast strains. In addition to classic galactose induction, we generated a β-estradiol-inducible version of each plasmid to facilitate editing in yeast strains that grow poorly on galactose. The plasmid-based system results in >95% editing efficiencies for point mutations and >50% efficiencies for markerless deletions, in a minimum number of steps and time. We provide a detailed step-by-step guide on how to use this system.

Indexed as

CRISPR-Cas SystemsGene EditingGenetic VectorsGenome, FungalSaccharomyces cerevisiaeEscherichia coliPlasmidsRNA, Guide, CRISPR-Cas SystemsRNA, Guide, CRISPR-Cas SystemsCRISPRgenome editingretronSaccharomyces cerevisiaeyeast

Identifiers

PMID40758833
PMCPMC12506651

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.